- Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's CSPCY messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization.
- CSPC's mRNA became China's first domestically developed mRNA shot as COVID cases decline across the country after a resurgence, Reuters reports.
- CSPS said its vaccine trials demonstrated incidents of adverse effects were substantially lower in an elderly group than an adult group.
- CSPS said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants. Its booster dose exhibited a good neutralization effect against Omicron subvariants BA.5, BF.7, BQ.1.1., XBB.1.5, and CH.1.1. in clinical trials.
- CSPC has built a manufacturing practice-compliant production plant for the vaccine. CSPC also produces critical raw materials and excipients.
- The vaccine could be stored at 2-8 degrees Celsius for a long time.
- In a study of 4,000 participants from December 10 - January 18, when China was going through a surge in infections, the vaccine showed an efficacy of 85.3%, 14 to 28 days after booster vaccination.
- CSPC also reported an 8.7% growth in 2022 net profit on Wednesday, backed by several newly launched generic drugs in China's national drug procurement program.
- China has declined to use global mRNA vaccines, and China's vaccines were deemed less effective than the Moderna, Inc MRNA and Pfizer, Inc PFE-BioNTech SE BNTX mRNA shots.
- Price Action: MRNA shares traded higher by 0.85% at $153.39 on the last check Wednesday.
- Image by Spencer Davis from Pixabay
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
